Good day, ladies and gentlemen, and welcome to the Verica Pharmaceuticals First Quarter 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's remarks, there will be a question and answer session. As a reminder, this conference is being recorded. I will now turn the call over to our host, Kevin Gardner of LifeSci Advisors. You may begin your conference.

Thank you, Operator. Hello, everyone, and welcome to Verica Pharmaceuticals' first quarter 2026 Corporate Update Conference Call. With me on the line this evening are Jason Rieger, President and Chief Executive Officer, Noah Rosenberg, Chief Medical Officer, John Kirby, Interim Chief Financial Officer, David Zawitz, Chief Operating Officer, and Chris Chapman, Chief Commercial Officer. As a reminder, during today's call, management will make forward-looking statements. These forward-looking statements are based on the company's current expectations and involve inherent risks and uncertainties. Verica's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements. Please see Verica's SEC filings for important risk factors. Verica cautions you not to place undue reliance on forward-looking statements and undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or changes in expectations. In addition, during today's call, management will discuss certain non-GAAP financial measures. These non-GAAP financial measures are in addition to, and not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. There are a number of limitations related to the use of these non-GAAP financial measures compared to their closest GAAP equivalents. The earnings release that the company issued today includes gap-to-non-gap reconciliations for these measures and is also available on the Investor Relations section of Verica's website. I'll now turn the call over to Verica's President and CEO, Jason Rieger.

Thank you, Kevin. Good evening, everyone, and thank you for joining us on our first quarter 2026 corporate update call. I am pleased to report that in the first quarter, we saw accelerating growth in market demand for Wycamp, setting new records for dispensed applicator units during the quarter and in the month of March. This growth continued after the end of the quarter as we observed further increased demand in April. Wycamp also achieved another significant milestone in February, as our partner, Tori Pharmaceutical, launched Wycant in Japan for patients with Molescum following their regulatory approval last year. Our hope is that Japan is only the beginning of our global expansion efforts for Wycant as we are actively working to expand the availability of Wycant into new markets around the world. While we grow the Wycant business, we're also advancing our product portfolio. As you may recall, in January we announced that the first patient had been dosed in our global Phase III program for the treatment of common warts, which represents a critical milestone in our strategy to expand into new indications. I'm proud to announce that we have achieved more than 50% of the currently targeted enrollment in the first Phase III trial, also known as COVID-2, and have begun enrolling patients in the long-term follow-up study, COV-IV, in this program. Our target is to initiate the second Phase III trial, known as COV-III, in this program by mid-2026. We also continue to advance our Phase III-ready asset, BP315, to the treatment of basal cell carcinoma as we have begun efforts to secure clinical supplies and select a CRO to support initiation of the Phase III program. BP-315 is garnering increasing attention within the dermatology community based on compelling proof-of-concept data from our Phase II program. I'll now provide a detailed update on our Wycamp commercial business. In the first quarter of 2026, we reported total revenue of $5 million, including U.S. Wycamp product revenue of $4.3 million, which was up 25.4% over the first quarter of 2025. First quarter U.S. WICANTH dispensed applicator units increased to $15,302, growing 51.3% over the first quarter of 2025. On a sequential basis, U.S. WICANTH revenue and dispensed applicator units increased 15.3% and 12.1% respectively, compared to the fourth quarter of 2025. As noted in our last call in March, while demand for Wycant in January was likely impacted by severe winter weather across the East Coast, demand accelerated sharply in February and continued into March, which saw the best monthly dispensed applicator unit total since the launch of Wycant. As we have now seen preliminary results for April, I am pleased to note that April dispensed applicator units also increased for March's then-record level, and our team worked diligently every day to help more healthcare providers treat molluscum with what we believe to be is the best treatment available, YCAMP. As we've noted in the prior quarters, as we continue to prioritize the ease of access for health care providers and their patients, we continue to make substantial investments in our copay assistance program, which is impacted during the first few months of each year by the annual reset of insurance plan deductibles in January. To ensure the broadest access to Wycanth for health care providers, we launched WycanthRx, our non-dispensing pharmacy, in the fourth quarter of 2025. Wycanth-Rx simplifies the process for both the healthcare provider and patient by performing an initial benefit investigation and then triaging to an in-network dispensing pharmacy based upon the patient's unique healthcare coverage. Although Wycanth-Rx is still in the early stage of rollout, it is being well-received, and in our view, will help further drive demand and coverage for Wycanth. We would again like to congratulate Tori Pharmaceutical, now a subsidiary of Shinogi, on their February commercial launch of Wycant in Japan for patients with molluscum. This milestone reflects the culmination of significant efforts by many team members from both companies. The launch of Wycant in Japan means that the commercial supply we provide to Tori has begun to offset Verica's portion of the clinical costs of the Common Warp program. As we announced in February, we also brought on board Chris Chapman as our new Chief Commercial Officer in the first quarter. Chris and his team are already doing an outstanding job in optimizing our resources to maximize the productivity of the WICAMP commercial efforts. Finally, as noted on our fourth quarter call, the Committee for Medicinal Products for Human Use of the European Medicines Agency provided positive feedback that supports the filing of a marketing authorization application for WICAMP as a treatment for molluscum. With no further Phase III clinical trials required for product approval, we are actively progressing through the next steps for submission in the EU. The EU represents a substantial market opportunity for WICAMS, and we look forward to evaluating potential commercialization partnerships in its large and underserved region. With respect to our pipeline, the common warts and basal cell carcinoma clinical programs continue to move ahead, representing what we believe can be multibillion-dollar opportunities. As I mentioned, in December 2025, we dosed the first patient in the first Phase III trial, COV-2, evaluating WICANTH for common warts, which continues to enroll patients. The second Phase III trial in the common wart program, COV-3, with sites in both the United States and Japan, is targeted to be initiated by mid-2026. If the Phase III program is successful, WICANTH could become the first therapy ever approved in the United States and Japan to treat common warts, a condition that impacts over 22 million people in the U.S. alone. As a reminder, Verica and Torrey will split the cost of the program 50-50, with Torrey funding the first $40 million of trial costs, representing approximately 90% of the current trial budget. We expect to repay our portion by offsetting future transfer payments, milestones, and royalties relating to Wycant sales in Japan. As a reminder, all of the efforts we are undertaking for the commercialization of Wycant for molluscum, lay the foundation for ultimate commercialization for the common warts indication if approved, and there will be significant overlap in the clinicians treating both molluscum and common warts with the ability to access the same applicator through the same distribution channels. With respect to VP315 for basal cell carcinoma, our program continues to drive strong interest with clinicians and patients alike as potential alternative approach to the existing surgical and non-surgical options. In our Phase II study, treatment with VP315 demonstrated a 97% objective response rate and an 86% reduction in overall tumor size, with more than half of the treated lesions achieving complete histological resolution. We continue to share additional data from the ongoing analysis of the results from the Phase II at scientific conferences. As reported last week, we will formally be presenting at the 2026 Society for Investigative Dermatology, or SID, at their annual meeting in Chicago later this week, and will be sharing additional data regarding the abscopal-like observations from the Phase II study. With a strong scientific foundation from our Phase II results and regulatory engagement, we have also recently completed several market research activities to better understand how VP315 would be received by various stakeholders. This work supports broad potential utilization and acceptance across general dermatologists, medical oncologists, and most surgeons, as well as office managers and payers. We also conducted market research to evaluate the patient perspective, which indicated that a substantial majority of patients would elect to try VP315 before other existing therapeutic options, regardless of whether they had previously been treated for skin cancer. While the best outcome for patients is to completely eliminate the tumor, which we have observed in many patients in our Phase II study, overall tumor size was reduced on an average of by 86%, which we view as clinically meaningful. This highlights the potential for VP315 to improve the patient experience by reducing the size and potential complexity of future procedures, even where surgical excision is ultimately required. In totality, this market research reinforces our conviction and enthusiasm for the potential of VP315 to change the paradigm for treatment of basal cell carcinoma. We continue to actively assess a variety of funding opportunities for this program and have initiated clinical and CMC activities to proactively prepare for the commencement of the Phase III program. As previously noted, Berica has retained 100% global commercial rights to WICANTH for all approved and potential indications outside of Japan, as well as full global rights to VP315 for non-metastatic skin cancers, including basal cell and squamous cell carcinoma. These programs represent a robust opportunity for potential partnership to create shareholder value and optimize global access to patients that can benefit most from these medicines. I'll now turn over the call to our Interim Chief Financial Officer, John Kirby, to review our first quarter 2026 financials.

Thanks, Jason. I'll now take a few minutes to summarize our financial results for the first quarter ended March 31st, 2026. Total revenue for the first quarter of 2026 was $5 million, consisting of $4.3 million of U.S. net Wykamp revenue and $0.7 million of license and collaboration revenue associated with our Tory partnership, compared to $3.4 million of U.S. net Wycanth revenue and $17,000 of license and collaboration revenue in the first quarter of 2025. Net Wycanth revenue in the first quarter of 2026 reflects shipments to our distribution partners offset by standard gross-to-net adjustments, including actual or anticipated pay-to-product returns, off-invoice discounts, distribution fees, rebates, and co-pay assistance program expenses. Gross product margins for the first quarter of 2026 were 87.3 percent compared to gross product margins of 87.6 percent for the prior year period. Cost of product revenue for the first quarter of 2026 was $0.5 million versus $0.4 million for the prior year period, consisting primarily of product costs related to the sale of WICANF. Research and development expenses of $3.9 million in the first quarter of 2026 increased by $1.5 million when excluding the impact of stock-based compensation compared to $2.3 million in the first quarter of 2025 due to increased spend on the Common Wards program. Selling general and administrative expenses of $10 million in the first quarter of 2026 increased by $1.3 million when excluding the impact of stock-based compensation compared to the expense of $8.8 million in the first quarter of 2025, driven primarily by increased commercial spend related to the expansion of our sales force. Gap net loss was $9.7 million, or 45 cents per share for the first quarter of 2026, compared to a gap net loss of $9.7 million, dollars, or $1.03 per share for the first quarter of 2025. On a non-GAAP basis, which excludes stock-based compensation, non-cash interest expense, and change in fair value of embedded derivatives, the first quarter of 2026 net loss was $8.8 million, or 41 cents per share, compared to a net loss of $8.3 million, or $0.88 per share for the first quarter of 2025. And finally, as of March 31, 2026, America had aggregate cash of $20.6 million, which is expected to fund operations into the first quarter of 2027. I'll now turn the call back over to Jason for closing remarks.

Thanks, John. We are steadfastly advancing our efforts to establish WICAMP as the new standard of care for Molescom and are seeing traction with our strongest quarter in dispensed applicator units since launch. We are also positioning our company to fully capture the significant opportunities which lie ahead for our advanced stage pipeline if these programs successfully complete their development and are approved. Based on our Phase II data, the feedback from the dermatology community, and alignment with the FDA on the Phase III program design, we believe BP315 truly has the potential to fundamentally change the treatment paradigm of basal cell carcinoma. In addition, the opportunity to expand YCAN's label into common warts would open in a new addressable patient population for which there currently remains no FDA-approved therapies. We believe each of these two opportunities represent significant potential upside for our company and for our shareholders, and we are excited about the future for Verica and the potential impacts for patients. With that, we'd be happy to answer your questions. Operator?

Thank you. And if you would like to ask a question, please press star 1 on your keypad. To leave the queue at any time, press star 2. Once again, that is star and one to ask a question. We'll take our first question from Stacey Kuh with TD Cowan. Please go ahead. Your line is open.

Hey there. Thanks so much for taking your questions. Congratulations on the enrollment progress for your common words program and also on the quarter for why can't. First, consensus for the year seems to be around kind of the mid-20 million. kind of range to the extent that you can comment but what are your your views given uh what seems to be very encouraging growing demand in april that's the first question um and then second i know this can be a little location specific but are you expecting to see seasonality with molluscum this year and what are you doing to ensure you can capture any type of increased rates in the summertime um would you also assume the why can't prescription hub services to start driving adoption and improving fulfillment around that timeframe. So that's the second question. The third is to get an update on the progress of expanding the sales force in regions that you're seeing good wide camp adoption. So just help us understand what you're seeing in terms of the additional stepwise expansion and if we should expect any additional updates with the sales course. Just help us understand the progress when it comes to why can't adoption and also maybe potentially why can't access. And then last, as you think about VP315, just maybe help us understand, as you think about phase three, where you expect the product to be positioned in the BCC treatment paradigm. What type of patient profile for BCC would opt for a product like this. Thanks so much.

Thank you, Stacey. I appreciate it. I think I made good notes on all of your questions. I'll do my best, but I'm sure you'll correct me if I miss any. Starting with the consensus, we're very excited about the progress we're making. We saw a good ending to the Q1, solid performance so far in April, and we're excited about the prospects of the year. It's premature to give guidance at this point, so we're going to leave that number alone, but what we're seeing right now, it gives us confidence on, you know, the growth that we're seeing and the performance over the course of the year. But with regards to seasonality, depending on, you know, where you look and who you ask, you know, there's all kinds of comments on when the seasonality would be, but overall, I think there's general consensus to see growth as you enter the spring and summertime, and I think that's where we are right now, and that could be contributing to some of the growth we're seeing, but a lot of it also comes down to the execution on the commercial side and the general adoption of YCANTH that we're starting to see. And I'll let Chris comment a little more on your questions regarding the Salesforce and the sales focus in a moment. But one of those tools that's certainly going to help, and we're starting to see some adoption is the YCANTH Rx and our hub to help support the routing of scripts and And importantly, the fulfillment of scripts, facilitating it for the clinicians and the patients to make that access as easy as possible. I'll let Chris comment a few minutes on your question on the commercial side, and then I'll round out the YCAMP on 315.

Thank you, Stacey, for the question. And, you know, as Jason mentioned in the opening, I joined in March. And I've been very pleased with what I've found in the organization. but there are areas for optimization. You mentioned the field force. Currently, we are deployed, and our territories do capture about 85% of the TAM. However, there are areas that we can optimize reach and frequency, and we are going through a kind of stem-to-stern reach and frequency exercise. We will be staffing to about approximately 50 representatives. There are numerous markets that could use additional manpower. And I think you're seeing in the momentum that we're building, slight tweaks to our deployment and our execution are yielding some momentum. And I remain cautiously optimistic on that. But, again, we're totally reevaluating our current targeting to optimize that reach and frequency, which, again, gives us the opportunity to optimize 85% that we're already deployed against.

Thanks, Chris. And then I'll let Noah comment a little bit on your question on VP315.

In terms of our Phase III program, our initial approach is to target patients with low-risk BCC, i.e. nodular and superficial, and to target similar populations that we saw in Phase II. Those would be primary tumors. I think broadly beyond Phase III, I think it's important to also recognize that we see this as potentially long-term neoadjuvant approach for complex and difficult to treat tumors. And very excited about the abscopal data, which has some implications potentially for patients who often present with multiple lesions at initial presentation.

Thanks, Noah. Thanks, Chris. To round that out, one of the feedback that we've generally seen from patients we've asked about their perspective on this treatment is those who are naive to ever having had treatment with basal cell or those who have had multiple basal cell experiences before seem to be very receptive towards the potential of BP-315 as a method to, as their first line of therapy to try and see if they can reduce the size or perhaps completely eliminate the lesion. And that bodes well, both for them as well as if, you know, proceeds down to Mohs or other procedures where that lesion is smaller and that surgical procedure would be simpler in terms of complication, potential scarring, you know, side effects, et cetera.

Super helpful. Thank you, as always.

Thanks, Stacey.

Thank you.

We will move next with Dennis Dink with Jefferies. Please go ahead.

Hello. This is Georgia Bank on the line for Dennis Dink. Thank you for taking your questions, and congratulations on the quarter. I guess another question on the 315 program and on the data, I guess showing reductions in untreated lesions consistent with the potential abscopal effect, how are you thinking about validating that signal going forward, and how should we think about the opportunity of that market where patients might have multiple lesions versus just a single, and what would that look like? And then a follow-up on the YCANTH-RX pharmacy model and how it's performing today, and what proportion of Scripps are routed through that pharmacy, and what are you seeing in terms of differences in prescription to, you know, treatment conversions or reimbursement success rates and so on?

So it's Noah here. I think in terms of the obscopal effect and the overall implications of the patient population, I think many patients present initially with multiple lesions. Often patients, especially those who've already had procedures, want a surgical alternative. So, again, we see this as complementary to surgery. But in some cases, patients may not want that surgery. And in some cases, they've got more than one lesion. So we believe that this data, while early and exploratory, is extremely encouraging. In terms of validating that data, we plan, as we've mentioned, two larger studies, 100 patients each in Phase 3. and we'll be able to explore and look at larger populations and look at that obscopal effect. I think it's important to note that regardless of whether the patients were contralateral or they were nearby in terms of the lesions, we still saw effects broadly, and I think that was extremely encouraging, and we're very excited to embark on that data.

This is David Zawitz speaking on WycanthRx. The WycanthRx performance has been good in the early few months since we launched it. It's an option that we provide to the prescribers who are looking to write the product. It's not mandatory. They can choose to write it if they are looking for the additional help with benefits investigations and with potentially processing prior offs if they're required. And so far, you know, we've been improving the program throughout the quarter since the launch, and it's been going well. We're not going to comment right now on sort of percentage of our total business that's running through that, but the adoption is growing, and it's going to be, it is proving to be a useful option for prescribers who are looking to use it.

Understood. Thank you. Thank you.

We will move next with Serge Bellinger with Needham Company. Please go ahead. Your line is open.

Hi, good afternoon. Thanks for taking our questions. First one, I guess, just on the the 1Q performance, just trying to understand the variability from quarter to quarter and intergrowth to nets to reconcile the difference between the applicator unit growth and sales number. And then secondly, can you maybe just talk about the competitor molluscum product that's currently in the market, whether it's been a headwind for Wycant or maybe there's been a tailwind due to the additional voice in the market promoting Molluscum. Thanks.

Serge, thanks for the question. It's Chris Chapman. And, you know, I think the variation certainly that you see between Q4 and Q1. Q4 historically is the most valuable month for manufacturers. Most of the patients have cleared their deductibles and people are refilling their prescriptions. Q1, you do have the deductible reset. So I think we saw a little bit of that. But as I mentioned in my prior comments, I'm really encouraged at the momentum that we saw coming out of Q1 into the first month of Q2, and there are a couple of reasons, and they all relate to the questions that have been asked here. One is WycanthRx, which provides a useful option for those physicians who need some additional support. The other, as you mentioned, is having additional share of voice. Having a second competitor in the market driving recognition and choosing to treat molluscum is a huge opportunity that we certainly are taking advantage of. The third, as I mentioned, being new to Verica, is the opportunity to do some basic optimization on reach and frequency on your targets. And so I think those three areas, but again, I would anticipate you're going to see a synergistic effect of share of voice in the marketplace, as well as those additional commercial levers that we're pulling. Expect to see more guidance as we get into Q3 and Q4. But right now, as I mentioned, cautiously optimistic, but impressed with the early results that we see.

Thanks, Chris. And as I said, sir, to follow up, what we've seen is this is a market dominated by a watch and wait mentality. And now that we have a viable option for treatment, And we believe YCANTS really addresses the unmet need by one to two treatments on average for most patients to get to a resolution that they're happy with in terms of their disease. We believe that will continue adoption and convert those from watching to actually getting treated. And awareness of the disease and that there's therapies out there bodes well for our program.

Thank you.

Thank you.

We will move next with Ram Silveragiu with H.C. Wainwright. Please go ahead.

Thanks so much for taking our questions. Just with respect to Europe, could you maybe elaborate on how you anticipate reference pricing to shake out as and when the product ultimately becomes eligible for market entry? And also, if you could give us a sense of post-approval, what the country-by-country cadence might be, which countries are most likely to be first in line for Wycant introduction. Thank you.

Thanks, Rob. I appreciate that. You know, we're still in the early stages of our Europe, you know, planning and strategy works. We have ongoing activities with regards to understanding pricing and pricing options and what reimbursement might look like there. We've explored that in a number of countries, and we're going to share that information as it's ripe to do so. In terms of countries, we're planning to have broad access across the EU. Obviously, there are some strategies on which countries may come first. In that, I would say we will probably be more consistent with traditional European rollouts, but we're going to evaluate that based on the feedback on a country-by-country basis and the addressable population, as well as the pricing that may differentiate across those countries. But that work is ongoing in parallel to our work to complete the regulatory submission activities.

Can you also just briefly comment on any underlying emergent trends among both unique prescribers and repeat prescribers of Y-CANF that you're seeing in the most recent data?

Yeah, I can speak to that. And we're seeing what you would expect to see, that the dermatologists dominate the early adoption. And you see that across classes. You also see it across competitors in this space. And as you would imagine, you're also seeing repeat prescribing in those earliest adopters. As we continue to expand that prescriber pool, you see more and more pediatricians coming in. So, you know, clearly those are the two largest segments, but as you might imagine, dermatologists were the early adopters in molluscum in the selection to both diagnose and to treat and to retreat additional patients.

Thank you.

We will move next with Kemp Dolliver with Brookline Capital Markets. Please go ahead.

What do you see as the gating factors behind demand now? You know, if you look back over the history of the launch, you know, there was reimbursement. There was compounded product in a lot of offices and on the market.

You know, how do you see – what do you see as the key things you need to overcome at this stage, assuming that those – the first couple things I mentioned have been resolved? yeah i don't know if i would if i would call access uh resolved certainly we've we've achieved a a steady state and a target access now we have the need to pull it through um you know into the children accounts of the pbm so there are still geographic opportunities uh for us to pull it through but i think the real gating factor is what you kind of hear a theme um in my answers here it's appropriate targeting and segmentation. You know, of course, we need to get that early adoption, and we need to get trial. But as you get into the pediatric segment, as Jason mentioned, you know, the biggest competitor is watchful waiting. And it's not that molluscum is not seen. It's with the prior lack of approved FDA-approved medications, it wasn't treated. And so now the The mitigating factor to us is to drive trial. YCANTH works, and when we see physicians trial it, they rewrite it. So for us, it's continuing to grow those prescribers concentrically out from the early adopters, from those deciles 10s, 9s, 8s, getting down into those lower-decile physicians, which will take us in more into that pediatric segment. So that becomes the real unique opportunity here in the next three to four quarters.

I was just going to follow up on that last point. Have you looked at whether there's a correlation between seniority of physician and willingness to trial?

When you mean seniority, what do you mean by that?

Age. I'm sorry, age.

Oh, interesting.

Because the medical tools, they used to teach them not to worry about it when you look at the senior physicians because there were no options.

But yeah, not not necessarily. But I will tell you this, where we do see some differential is your physician extenders, those on the front lines and the trenches, your nurse practitioners, your PAs. They are very, very open to treating. And so I guess in a way, you know, you might be able to extrapolate that to age. But I think that's more of a relevant dynamic are the nurse extenders or physician extenders. But, yeah, I really don't see it as age. But I will say, you know, dermatology as a whole is very familiar with catheridin. Primary care, less so. So I think the trial that we've seen early is to be expected. The adoption that we're now seeing in dermatology is to be expected. And the opportunity remains as we expand out into pediatricians.

And, Kim, to follow up, two more points to address some of your comments. you know, we've spent the last year working on distribution and access and availability of the product for clinicians who want to treat. And this quarter, you know, just, you know, we just announced, you know, in our release, which we crossed over 100,000 applicators that have been dispensed since launch. You know, one of the things, you know, as presuppers to the early adopters versus starting to expand beyond that, you start to get a critical amount of adoption and utilization outside post-clinical trials, and that gives the later adopters and those who like to watch and take their time, you know, data to see that the safety profile, you know, is consistent with what we saw in the clinical studies, the efficacy is being consistent with what we're seeing, and so both of those things really bode well for, you know, those next wave of adopters to start to come aboard, and we've worked very hard to make it the access to be easy with our co-pay support, you know, our medical education, you know, and, you know, just awareness of the

product for treatment in Obeloscum.

Thank you. We will move next with Dev Prasad with Lucid Capital Markets.

Please go ahead.

Thank you for taking our question and congrats on the progress. I have a couple. One following up to the last one, I'm not sure if you answered it or not, but are you seeing why can't growth primarily from new prescriber entering this launch curve or from higher utilization from existing high volume account? And second is, what are the next getting steps for EU submission and potential launch? Thank you.

Thanks for the question. And we're really seeing both. Those prescribers who trialed early are continuing to prescribe, but we are seeing a much quicker acceleration as we get into that early majority segment of the physician cohort. So I think we're going to continue. We have to drive both. Of course, when you do have a competitor come out, those earliest adopters are going to trial that brand, which is a good thing. But we are seeing continued growth in both segments, and we'll continue to focus on the highest deciles, 10 through 8, to make sure that we, you know, we have that secure as we continue to expand, you know, into the rest of the market.

With regards to Europe, you know, there's obviously a number of steps that you have to go through. We have received our initial scientific advice regarding the general scope of what a submission would look like for approval. Now we need to go through the process, you know, for example, securing, you know, pediatric investigation waivers, you know, rapid tour assignment, et cetera. And so we're going through that process now. And as indicated previously, you know, Verica has retained global rights to White Camp outside of the United States, except for Japan, which is, you know, controlled by Tory. If we have those rights and, you know, we'll continue to explore that, you know, for a European partner to support both the commercialization process to address some of the earlier questions as well.

Great.

Thank you.

Thank you. And at this time, there are no further questions in queue. I will now turn the meeting back to CEO Jason Rieger for closing comments.

Thank you, Operator, and thank you, everyone, for your time and attention. I'd like to thank you for joining us this evening, and we look forward to providing more updates on our progress throughout 2026. Have a nice evening.

Thank you. This brings us to the end of today's meeting. We appreciate your time and participation. You may now disconnect.